Pharmaceutical M&A deals in 2009
4 February 2010
Following 2008, when pharmaceutical sector merger and acquisition activity was on a relatively small scale in terms of the size of deals announced, 2009 was a bumper year.
According to The Pharma Letter's records, there were 92 pharmaceutical acquisitions consummated during 2009 (with several others announced but failing), compared with 113 the previous year. Of the 2009 announcements, 16 deals exceeded a value of $1 billion (see separate story for a full commentary on the deals.) The full list can be seen below.
| Company | Partner | Deal value $ | Complete |
| Abbott Labs (US) | Advanced Medical Optics (US) | $2.8 billion | Feb 2009 |
| Abbott (US) | Visiogen | $400.0 million | Oct 2009 |
| Abbott (US) | Solvay (Belgium) Pharma unit | $6.6 billion | 1st-qtr 2010 |
| Adamis Pharma (USA) | La Jolla Pharma | Undisclosed | TCB |
| Alcon (Swiss) | ESBATech (Swiss) | $439.0 million | TBC |
| AstraZeneca (UK) | Novexel (France) | $505.0 million | TCB |
| BioMarin (US) | Huxley Pharma (US) | c$58.5 million | Oct 2009 |
| BioSante Pharma (US) | Cell Genesys (US) | $38.0 million | Oct 2009 |
| Biovitrum (Sweden) | Swedish Orphan (Sweden) | $493.0 million | Dec 2009 |
| Bristol-Myers Squibb (US) | Medarex (US) | $2.4 billion | Sep 2009 |
| Celgene (US) | Gloucester Pharma (US) | $640.0 million | 1st-qtr2010 |
| Cellidex Thera (US) | CuraGen (US) | $94.5 million | Oct 2009 |
| Cephalon (US) | Arana Therapeutics (Australia) | $205.0 million | Aug 2009 |
| Dainippon Sumitomo (Japan) | Sepracor (US) | $2.6 billion | Oct 2009 |
| Deerfield Management | NitroMed (US) | $36.0 million | Feb 2009 |
| Eisai (Japan) | AkaRx (US) | $255.0 million | TBC |
| Endo Pharma (US) | Indevus Pharma (US) | $637.0 million | Feb 2009 |
| Evolva (Swiss) | Arpida (Swiss) | Undisclosed | Dec 2009 |
| Evotec (Germany) | RSIPL (India) | $3.5 million | Aug 2009 |
| Genesis Pharma (US) | Hongrui Pharma (China) | $16.0 million | Mar 2009 |
| Gen-Probe (US) | Tepnel Life Science (UK) | $132.2 million | Apr 2009 |
| Gilead Sciences (US) | CV Therapeutics (US) | $1.4 billion | Apr 2009 |
| GlaxoSmithKline (UK) | Bristol-Myers Squibb (Pakistan) | $365.0 million | 2009 |
| GlaxoSmithKline UK) | UCB Emerging Market units | $676.0 million | 2009 |
| GlaxoSmithKline (UK) | Stiefel Labs (US) | $3.6 billion | July 2009 |
| GlaxoSmithKline (UK) | Aspen Pharmacare (19% stake) | $593.6 million est | Dec 2009 |
| GlaxoSmithKline (UK) | Intercell (Austria; 5% stake) | $57.4 million | Dec 2009 |
| GPC Biotech (German) | Agennix (US) | Undisclosed | Mar 2009 |
| HalcyGen (Australia) | Mayne Pharma Int (Australia) | 415.0 million | Oct 2009 |
| Hard to Treat Medicine (China) | Shenzen Mellow Hope (China) | Undisclosed | Mar 2009 |
| Helsinn (Switzerland) | Sapphire Therapeutics | Undisclosed | Feb 2009 |
| Hisamitsu Pharma (Japan) | Noven Pharma (US) | $428.0 million | Aug 2009 |
| Hospira (US) | Orchid Chem & Pharma (India) (injectable generics business) | $400.0 million | TBC |
| Integrated DNA Tech (US) | VH Bio's oligo business | Undisclosed | 2009 |
| Inviragen (US) | SingVax (Singapore) | Undisclosed | Oct 2009 |
| Johnson & Johnson (US) | Cougar Biotechnology | $1.0 billion | Jul 2009 |
| Johnson & Johnson (US) | Crucell ' 18% stake | $443.3 million | Sept 2009 |
| Laboratory Corp of America (US) | Monogram Biosciences (US) | $106.7 million | Aug 2009 |
| LEO Pharma (Denmark) | Peplin (US, Australia) | $287.5 million | Nov 2009 |
| Ligand Pharma (US) | Neurogen (US) | $11.6 million | Dec 2009 |
| Ligand Pharma (US) | Metabasis Thera (US) | $3.2 million | Nov 2009 |
| Lundbeck (Denmark) | Ovation Pharma (US) | $900.0 million | Mar 2009 |
| Lundbeck (Denmark) | LifeHealth (UK) | $147.0 million | Jul 2009 |
| Medicines Co (US) | Targanta Therapeutics | $42.0 million | Feb 2009 |
| MediciNova (US) | Avigen (US) | $37.0 million | Dec 2009 |
| Merck & Co (US) | Schering-Plough (US) | $41.1 billion | Nov 2009 |
| Merck & Co (US) | Avecia Biologics (UK) | Under $1 billion TBC | |
| Merck KGaA (Germany) | Bangalore Genei (India) | Undisclosed | Oct 2009 |
| Midas BidCo (Goldshield management team) | Goldshield (UK) | $280 million | Dec 2009 |
| Mylan (US) | Matrix Labs (India) (29% not already owned) | $133.0 million | 2009 |
| Myriad Pharma (US) | Javelin Pharma (US) | $96.0 million | TBC |
| Nippon Chemiphar (Japan) | Nihon Pharma (taking over Ranbaxy share of the JV) | Undisclosed | TCB |
| Novartis (Swiss) | EBEWE Pharma (Austria) | $1.2 billion | Sept 2009 |
| Novartis (Swiss) | Zheijian Tianyuan (China) | $125 million | TBC |
| Novartis (Swiss) | Corthera (US) | $120.0 million (Plus possible $500 million on milestone successes) | TCB |
| Onyx Pharma US) | Proteolix (US) | $850.0 million | Nov 2009 |
| Opko Health (US) | Pharma Genexx (Chile) | $16.0 million | Dec 2009 |
| OXiGENE (US) | VaxGen (US) | $22.0 million | TBC |
| Pfizer (US) | Wyeth (US) | $68.0 billion | Oct 2009 |
| Pharmexa (Denmark) | Affitech (Norway) | Merger | Jun 2009 |
| Piramel (India) | Minrad International (US) | $40.0 million | 2009 |
| PPD (US) | Magen Biosciences (US) | $14.5 billion | Apr 2009 |
| Progen (Australia) | Avexa (Australia) | $55.3 million | 2009 |
| Proximagen Neuro (UK) | Cambridge Biotech (UK) (acquired from Biovitrum of Sweden) | Undisclosed | Nov 2009 |
| Qiagen (Netherlands) | SA Biosciences (US) | $90.0 million | Dec 2009 |
| Raptor Pharma (US) | TorreyPines (US) | Undisclosed | Sept 2009 |
| Roche (Swiss) | Genentech (USA) | $46.8 billion (42% not already owned) | Apr 2009 |
| Sanofi-Aventis (France) | Zentiva (Czech) | $2.3 billion | Mar 2009 |
| Sanofi-Aventis (France) | Medley SA (Brazil) | $220.0 million | Mid-2009 |
| Sanofi-Aventis (France) | Laboratorios Kendrick (Mexico) | Undisclosed | Apr 2009 |
| Sanofi-Aventis (France) | BiPar Sciences (US) | Undisclosed | 2nd qtr |
| Sanofi-Aventis (France) | Shantha Biotechnics (India) | $613 million | Aug 2009 |
| Sanofi-Aventis (France) | Fovea Pharma (France) | $542 million | Dec 2009 |
| Sanofi-Aventis (France) | Chattem (US) | $1.9 billion | TCB |
| Santhera (Swiss) | Juvantia Pharma | Undisclosed | Oct 2009 |
| Schwabe Pharma (German) | Dr Peithner Holdings | Undisclosed | May 2009 |
| Sigma-Tau (Italy) | Enzon (US) Specialty Pharma business | $327.0 million | Dec 2009 |
| Silence Therapeutics UK) | Intradign (US) | Undisclosed | Jan 2010 |
| Simcere Pharma (China) | Jiansu Yanshen (China) 37% stake | $28.6 million | 2009 |
| Sinclair Pharma (UK) | Lab Novo Pharma (Spain) Remaining 50% holding | Undisclosed | Feb 2009 |
| Stem Cells (USA) | Stem Cells Sciences (UK) | Undisclosed | May 2009 |
| Takeda (Japan) | IDM Pharma (US) | $75.0 million | July 2009 |
| Teva (Israel) | OncoGenex (US) (small stake) | $10.0 million | TCB |
| Teva (Israel) | Taisho Pharma Ind (Japan) (majority stake min.66.7%) | Undisclosed | Dec 2009 |
| Tolmar (US) | Zila (US) | $4.0 million | Sept 2009 |
| Tolmar (USA) | QLT (Canada)'s US unit | $230.0 million | Oct 2009 |
| Tongjitang (China) | Anhui Jingfanag (China) | $8.8 million | Apr 2009 |
| Valeant (US) | EMO-PHARMA (Poland) | $28.0 million | May 2009 |
| Valeant (USA) | Lab Dr Renaud (Canada) | $21.8 million | TCB |
| Warner Chilcott (Irish) | Procter & Gamble Rx Pharma business | $3.2 billion | Oct 2009 |
| Watson Pharma (US) | Arrow Pharma (US) | $1.75 billion | Dec 2009 |
| Wyeth (US) | Thiakis (UK) | $150.0 million | Jan 2009 |
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
7 October 2024
7 October 2024
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze